ClinicalTrials.gg
RecruitingNCT06191965Updated Nov 19, 2026

MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction

A Phase 2/3 interventional study of MitoQ and Placebo in Schizophrenia and Related Disorders, Mitochondrial Alteration and Cognitive Impairment, sponsored by Mclean Hospital. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Mclean Hospital · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Schizophrenia by Mclean Hospital — 4 open to participants now, 4 under way, 1 of them phase 3. Schizophrenia · Mclean Hospital.

Planned enrollment
3rd of 14
100 · median 48
Started
2024
with 2 others
Phase 2/3
2 of 15
1 open now
Registered
15th of 15
by date

Among the 15 studies in Schizophrenia by Mclean Hospital, this one is the 3rd largest by planned enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2024, is one of 2 in phase 2/3, and was the 15th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 15 studies in Schizophrenia by Mclean Hospital are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Schizophrenia by Mclean Hospital, or all of them as a file.
02

Study summary

The goal of this double-blind, placebo-controlled randomized clinical trial is to test the effect of 12 weeks of orally administered MitoQ (mitoquinol mesylate) supplementation on cognition in 50 people with early phase schizophrenia-spectrum disorders (E-SSD) who have mitochondrial dysfunction (called high risk, or HR). Cognitive impairments in SSD can cause significant disability. Yet, there are no effective treatments for cognitive impairments in SSD. It has been shown that alterations in a certain type of brain cell (parvalbumin interneurons, or PVI) underlie cognitive deficits in SSD. These PVI, which fire at a fast rate, utilize high amounts of energy from the mitochondria and are highly vulnerable to oxidative stress. MitoQ is an antioxidant. Research has shown that, in mice, MitoQ can reduce oxidative stress in the mitochondria. The main question that this clinical trial aims to answer is:

  • Does MitoQ supplementation, compared to placebo, improve cognition in HR patients?

Secondary questions that this clinical trial aims to answer are the following: Does MitoQ supplementation, compared to placebo:

  • Improve positive and negative symptoms of SSD in HR patients?
  • Improve functioning in HR patients?
  • Improve/normalize blood markers of mitochondrial dysfunction in HR patients?

The investigators will enroll 100 individuals with E-SSD. These enrolled participants will participate in an initial screening visit to determine if they qualify for the actual clinical trial. At the screening visit, the investigators will ask about psychiatric history to determine diagnosis; ask about medical history; do a physical exam; collect blood and urine samples; do a pregnancy test; and ask participants to bring in their current medications in their original packaging so it is known what they are taking.

After the screening visit, the investigators will invite 50 HR patients (identified with a blood test) to continue with the clinical trial. Participants who qualify for the clinical trial will be asked to:

  • Take a supplement (MitoQ or placebo) once per day for 12 weeks in addition to their usual medications.
  • Come in for a study visit every 4 weeks over the 16-week study period. At these study visits, the investigators will do a physical exam; ask about symptoms and side effects; take blood and urine samples; and ask questions about general health and well-being, quality of life, mental health, emotional health, and mood. At visits 1 (baseline) and 4 (12 weeks), participants will also take a cognitive assessment.
Read the detailed description

The planned clinical trial aims to test the effect of an oral administration of MitoQ on neurocognition, psychiatric symptoms, functioning, and exosomal levels of the mechanism-based biomarkers miR-137 and COX6A2 in HR individuals in the early phase of schizophrenia-spectrum disorders (E-SSD).

The investigators propose to implement a randomized, double-blind, placebo-controlled stratified clinical trial with MitoQ as an adjunctive treatment for 12 weeks in a sample of n=25 patients with early-stage psychosis. The primary outcome will be a change in global cognition as defined by the MATRICS Consensus Cognitive Battery (MCCB). Specifically, the hypothesis is that MitoQ will lead to an increase in the MCCB cognitive composite score in the subgroup of early psychosis patients displaying peripheral markers of mitochondrial dysfunction.

To test whether the oral administration of MitoQ will improve neurocognition in the HR subgroup, the investigators will conduct a double-blind, randomized, placebo-controlled trial at two sites (McLean Hospital and Yale School of Medicine). The overall goal of the study is to assess 100 patients (50 per site) with early phase psychotic disorders for HR status (with a blood test) and randomize 50 HR patients (25 per site). This 50% proportion is based on the fact that, in the Early psychosis Lausanne Cohort, the HR patients constitute half of the entire cohort 1.

The two sites will conduct research procedures in parallel, following the same protocol, but undergo independent processes of human subjects review and oversight by each site's local institutional review board. Thus, at McLean (for which the Mass General Brigham IRB will serve as the IRB of record), the investigators plan to assess 50 early psychosis patients for HR status and randomize 25 HR patients to MitoQ vs. placebo. An equivalent number of participants will be enrolled and randomized at Yale (for which the Yale IRB will serve as the IRB of record). With 20% attrition, it is expected that there will be 20 completers per site at the end of the study.

Patients will be asked to take part in a clinical trial consisting of a randomization to either MitoQ or placebo for 12-weeks and a follow up visit 4 weeks after the end of the last intervention.

Patients who are in the first 5 years of treatment for a SCZ-spectrum disorder will be eligible 30. All eligible patients with an early phase psychotic disorder will be recruited for this study. Patients who enroll in the study will undergo a blood test during the screening visit to determine if their plasma mIR137 and COX6A2 levels are consistent with high risk (HR) or low risk (LR) status. Once this categorization has been made, only HR patients will be invited to proceed with the study. HR patients who wish to continue will be assigned randomly to either the MitoQ or the placebo arm.

Primary outcome:

- Our primary outcome is change in cognitive function, as measured by change in the composite MCCB score from baseline to 12 weeks.

Secondary outcomes:

  • The investigators will also measure each specific neurocognitive domain within the MCCB because each domain includes differential information. For example, attention/vigilance appears to best differentiate HR from LR patients.
  • The investigators will also include change in clinical outcomes and blood biomarkers as described in the sections below:

    1. Global Assessment of Functioning (GAF) and the Social and Occupational Functioning Assessment Scale (SOFAS)
    2. Positive and negative symptoms (Positive and Negative Syndrome Scale- PANSS)
    3. Blood biomarkers: Improvement/normalization of the exosomal levels of miR-137 and COX6A2 to demonstrate target engagement.
    4. Clinical global impression (CGI) score: Change in global illness severity, measured with the Clinical Global Impressions-Severity (CGI-S).

Safety Outcomes:

All adverse effects, vital signs, ED visits and hospitalizations, and the Generic assessment of side effects scale (GASE-D) score will be recorded at every visit. There will also be an EKG obtained at the screening visit, at the start of treatment (week 0), and at week 12.

03

Conditions studied

  • Schizophrenia and Related Disorders
  • Mitochondrial Alteration
  • Cognitive Impairment
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 18 to 35 years old
  • Patients who have been diagnosed with one of the following schizophrenia-spectrum disorders: schizophreniform disorder, schizophrenia, schizoaffective disorder, unspecified psychosis.
  • Less than five years in treatment for psychosis (note that the duration of psychosis may be longer than 5 years, but this is more difficult to ascertain and therefore less reliable as an inclusion criterion).
  • PANSS score \< 75
  • Ability to provide .

Exclusion criteria

Exclusion Criteria:

  • Meeting criteria for any substance use disorder diagnosis in the past 6 months will be exclusionary EXCEPT tobacco and mild/moderate cannabis use disorder, which will be included
  • Any acute medical condition requiring actively changing treatment (e.g., disorders, acute infections, /AIDS, cancer, renal failure, hepatic dysfunction, cardiovascular disease, or abnormal thyroid findings). Individuals with chronic medical conditions that are stable will not be excluded (e.g., person with hypothyroidism who is taking thyroid hormone replacement and has TSH levels within the normal range; person with well-managed diabetes; etc.)
  • Epilepsy or another seizure disorder
  • Intellectual disability (e.g., history of IQ \< 70).
  • Under legal guardianship
  • Not English speaking. The questionnaires, instruments, cognitive assessments used in this research study have not been translated, validated, or studied extensively in non-English-speaking individuals. For this reason, we will not enroll individuals who do not speak English to maintain validity in the study.
  • MitoQ allergy
  • Treatment with antioxidants: omega3 (fish oil), Vitamin E, Vitamin C, multivitamins, NAC (N-acetyl cysteine) within the last 14 days. If the treatment is taken without prescription, we will ask the patient to stop using it for at least 14 days to become eligible for the present study.
  • Children and adolescents, pregnant women, women who have the intention to become pregnant during the course of the study, and breastfeeding women are excluded from the study. This is because no MitoQ pharmacokinetic data are available in pediatric populations, pregnancy or breastfeeding.
  • Lack of safe , defined as: female participants of , not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases. Female participants who are surgically sterilized/hysterectomized or for longer than 2 years are not considered as being of childbearing potential.
  • Enrollment of study staff, their family members, and other dependent persons
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    MitoQ

    20 mg 2 capsules once daily for 12 weeks (total daily dose 40 mg)

    Drug: MitoQ

  • Placebo comparator
    Placebo

    2 capsules (identical in appearance to MitoQ capsules) once daily for 12 weeks

    Drug: Placebo

Interventions

  • DrugMitoquinoneStudies of MitoquinoneMitoquinone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    MitoQ is a synthetic analogue of coenzyme Q10. It is produced by the company Antipodean Pharmaceuticals and is formulated as a stable yellow powder suitable for oral formulation, prepared as capsules of white color. It is a commercial dietary supplement sold over the counter as an antioxidant, to be taken orally once or twice a day. It has subsequently been tested for various clinical conditions in humans. 1. Molecular formula: C38H47O7PS (C37H44O4P.CH3O3S) 2. CAS number: 444890-41-9 (phosphonium cation) 3. Molecular weight: 678.81 4. MitoQ capsules: The standard commercial posology is a 20 mg daily dose. All formulations are produced following Good Manufacturing Practice (GMP) standards (https://www.who.int/medicines/areas/quality\_safety/quality\_assurance/TRS986annex2.pdf?ua=1). 5. MitoQ will be administered in oral capsules provided by the manufacturer Antipodean Pharma, to be taken once daily, one hour before breakfast. The daily dose will be 2 pills, i.e., 40 mg MitoQ.

    Also known as: mitoquinol mesylate, Chemical name: [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl) decyl] triphenyl phosphonium mesylate

  • DrugPlacebo

    Placebo pills in identical appearance to the MitoQ capsules will be produced and provided by Antipodean Pharma and given to the patients in the control arm two per day to be taken one hour before breakfast. The composition of the placebo is tapioca starch, microcrystalline cellulose, hypromellose, silica-colloidal anhydrous, purified water, carrageenan, and pectin.

    Also known as: Sugar pill

06

What researchers measure

Primary outcomes

  1. Change from baseline in the MATRICS Consensus Cognitive Battery (MCCB) composite score at week 12

    The MCCB evaluates cognitive functioning in schizophrenia and related disorders. It includes ten tests that measure seven cognitive domains including speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. The MCCB composite score has been shown to be highly correlated with general level of intellectual ability.

    Time frame: Baseline and week 12

Secondary outcomes

  1. Change from baseline in the MATRICS Consensus Cognitive Battery (MCCB) attention/vigilance score at week 12

    The MCCB evaluates cognitive functioning in schizophrenia and related disorders. It includes ten tests that measure seven cognitive domains including speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. Research has suggested that the attention/vigilance domain best differentiates HR from low risk (LR) patients.

    Time frame: Baseline and week 12

  2. Change from baseline in the MATRICS Consensus Cognitive Battery (MCCB) speed of processing score at week 12

    The MCCB evaluates cognitive functioning in schizophrenia and related disorders. It includes ten tests that measure seven cognitive domains including speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition.

    Time frame: Baseline and week 12

  3. Change from baseline in the MATRICS Consensus Cognitive Battery (MCCB) working memory score at week 12

    The MCCB evaluates cognitive functioning in schizophrenia and related disorders. It includes ten tests that measure seven cognitive domains including speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition.

    Time frame: Baseline and week 12

  4. Change from baseline in the MATRICS Consensus Cognitive Battery (MCCB) verbal learning score at week 12

    The MCCB evaluates cognitive functioning in schizophrenia and related disorders. It includes ten tests that measure seven cognitive domains including speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition.

    Time frame: Baseline and week 12

  5. Change from baseline in the MATRICS Consensus Cognitive Battery (MCCB) visual learning score at week 12

    The MCCB evaluates cognitive functioning in schizophrenia and related disorders. It includes ten tests that measure seven cognitive domains including speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition.

    Time frame: Baseline and week 12

  6. Change from baseline in the MATRICS Consensus Cognitive Battery (MCCB) reasoning and problem solving score at week 12

    The MCCB evaluates cognitive functioning in schizophrenia and related disorders. It includes ten tests that measure seven cognitive domains including speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition.

    Time frame: Baseline and week 12

  7. Change from baseline in the MATRICS Consensus Cognitive Battery (MCCB) social cognition score at week 12

    The MCCB evaluates cognitive functioning in schizophrenia and related disorders. It includes ten tests that measure seven cognitive domains including speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition.

    Time frame: Baseline and week 12

  8. Change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score at week 12

    The PANSS is a 30-item clinician-administered rating scale that evaluates the severity of positive, negative, and general psychopathology symptoms in schizophrenia and related psychotic disorders. Each of the 30 items is rated from 1 to 7, ranging from absent to extreme. The total PANSS score, which is the sum of the three subscales ranges from 30 to 210 (7-49 for the positive scale, 7-49 for the negative scale, and 16-112 for the general psychopathology scale).

    Time frame: Baseline and week 12

  9. Change from baseline in the Social and Occupational Functioning Assessment Scale (SOFAS) score at week 12

    The SOFAS is a global rating of current functioning ranging from 0 to 100, with lower scores representing lower functioning. The SOFAS differs from the similar Global Assessment of Functioning (GAF) scale by focusing on social and occupational functioning independent of the overall severity of the individual's psychological symptoms. The SOFAS also differs from the GAF scale in assessing impairments in functioning due to physical limitations, as well as those due to mental impairments.

    Time frame: Baseline and week 12

  10. Change from baseline in the Global Assessment of Functioning (GAF) score at week 12

    The GAF score is used to rate how serious a mental illness may be. It measures how much a person's symptoms affect their day-to-day life on a scale of 0 to 100, with lower scores representing lower functioning.

    Time frame: Baseline and week 12

  11. Change from baseline in the Clinical Global Impressions Severity (CGI-S) scale score at week 12

    The CGI-Severity (CGI-S) scale asks the clinician one question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" which is rated on the following seven-point scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. This rating is based upon observed and reported symptoms, behavior, and function in the past seven days.

    Time frame: Baseline and week 12

  12. Change from baseline in the level of miR-137 at week 12

    miR-137 (or microRNA-137) is a short exosomal (non-coding) RNA molecule that functions to regulate the expression levels of other genes. mIR-137 is a marker of mitochondrial dysfunction in early psychosis (with higher levels associated with greater mitochondrial dysfunction). Changes in mIR-137 in combination with changes in COX6A2 will help us determine the success of target engagement.

    Time frame: Baseline and week 12

  13. Change from baseline in the level of COX6A2 at week 12

    The protein COX6A2 is a subunit of cytochrome c oxidase complex IV specific to parvalbumin interneurons, which are known to be altered in schizophrenia. COX6A2 is a marker of mitochondrial dysfunction in early psychosis (with lower levels associated with greater mitochondrial dysfunction). Changes in COX6A2 in combination with changes in mIR-137 will help us determine the success of target engagement.

    Time frame: Baseline and week 12

07

Study locations

1 of 3 sites recruiting
08

References and documents

Publications

  • Khadimallah I, Jenni R, Cabungcal JH, Cleusix M, Fournier M, Beard E, Klauser P, Knebel JF, Murray MM, Retsa C, Siciliano M, Spencer KM, Steullet P, Cuenod M, Conus P, Do KQ. Mitochondrial, exosomal miR137-COX6A2 and gamma synchrony as biomarkers of parvalbumin interneurons, psychopathology, and neurocognition in schizophrenia. Mol Psychiatry. 2022 Feb;27(2):1192-1204. doi: 10.1038/s41380-021-01313-9. Epub 2021 Oct 22. PubMed 34686767 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Jan 2027, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2023
First posted
Jan 5, 2024
StartActual
Jun 1, 2024
Primary completionEst.
Jan 31, 2027
CompletionEst.
Jan 31, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and oversight details
1 update, last Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Minor edits only
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06191965
Lead sponsor
Mclean Hospital
Collaborators
Yale University, University of Lausanne
Responsible party
Dost Ongur (Professor of Psychiatry/Psychotic Disorders Division Chief, Mclean Hospital) — Principal investigator
First posted
Jan 5, 2024
Start date
Jun 1, 2024
Primary completion
Jan 31, 2027 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Dost Ongur, MD, PhD
Contact
dongur@mgb.org
6178553922
Steve Prete, RN
Contact
sprete@mgb.org
6178552273
Dost Ongur, MD, PhD
principal investigator · Mclean Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mitoquinone

Start the discussion